A payer value story is the argument for why a technology is worth funding, expressed for a specific payer in a specific health system. The clinical evidence behind it is the same everywhere. Almost everything else — the comparator, the standard of care, the epidemiology, the cost structure, the label, the language — is local.
Localisation is therefore not translation. It is re-argument against a different baseline, using the same evidence, within a different set of constraints. For the wider picture, see AI for market access and HEOR.
What actually changes between markets
The comparator and standard of care. The most consequential variable. A treatment positioned against best supportive care in one market may face an established active comparator in another — the value argument changes shape entirely.
The label. What is on-label varies by market. A claim compliant in one jurisdiction may be non-compliant in another, and this constraint has to be enforced by the system rather than remembered by the reviewer.
Epidemiology, economics and what the payer values. Prevalence and local burden, pricing reference points, and whether the payer weighs cost-effectiveness, budget impact, clinical need or equity considerations differently.
How localisation works over a governed evidence base
Evidence is held once, structured, versioned and provenance-tracked. Each market is a view over it — defined by that market's label, comparator set, authoritative local sources and payer requirements. Generation for a market retrieves within that view; evidence outside it is not available to the draft, which is what makes the on-label constraint structural rather than procedural.
Local sources — epidemiology, cost data, treatment guidelines — sit alongside global evidence, and getting them into the governed base is usually the harder half of a localisation deployment, since they are typically held by local affiliates in inconsistent formats. Language is the last step, not the first — systems that treat localisation as translation produce fluent documents making the wrong argument against the wrong comparator.
Where Eclypse sits: the same governed evidence base and provenance model used for dossier generation supports market-specific views — see AI value dossier automation for the underlying pipeline.
Data residency can constrain this architecture further — see data residency for healthcare AI and sovereign AI for what changes when local evidence itself is subject to localisation requirements.
Common questions about localising value stories.
What is payer value story localisation?
Adapting the argument for why a technology is worth funding to a specific market's comparator, label, epidemiology and payer priorities, using the same underlying clinical evidence.
Why can't a global value story simply be translated?
Because the comparator and standard of care differ by market, changing the shape of the argument rather than its wording. Translation alone produces a fluent argument against the wrong comparator.
How do you keep localised content on-label across markets?
By making the market's label define the retrieval scope, so evidence outside it is unavailable to generation, and verifying output against the label before review.
What is the hardest part of localising value stories at scale?
Acquiring and governing local sources — affiliate-held epidemiology and guidelines in multiple languages and formats, owned by teams with competing priorities.
Bring us two markets that need the same evidence argued differently.
Book a working session
ECLYPSE
AI
Our proprietary AI orchestration platform for healthcare: one engine, a registry of reusable task modules and domain agents, and a governed knowledge base — deployed inside your walls and run by your team.